SENORES PHARMACEUTICALS L Q2 Results FY27: PAT Falls 76.16% to Rs 7.72 Cr, Revenue Rs 35.65 Cr

SENORES PHARMACEUTICALS L (SENORES) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. On the results date, revenue came in at Rs 35.65 Cr and net profit at Rs 7.72 Cr, both below the year-ago quarter. SENORES PHARMACEUTICALS L Q2 Results FY27 are the base for everything that follows.

This SENORES PHARMACEUTICALS L Q2 Results analysis by Univest covers the financial highlights, business drivers, outlook and risks. The results analysis starts with the highlights table below, which lists revenue and net profit for the quarter and for the year-ago period, so the YoY growth figures can be read directly.

Click Here – Get Free Investment Predictions

SENORES PHARMACEUTICALS L Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 35.65 Cr	Rs 161.76 Cr	-77.96% YoY
Net Profit (PAT)	Rs 7.72 Cr	Rs 32.38 Cr	-76.16% YoY

Source: company filing for SENORES PHARMACEUTICALS L Q2 Results FY27, 29 October 2026. Figures in Rs Crore.

Key Takeaways from SENORES PHARMACEUTICALS L Q2 Results: What Stands Out

• Revenue: Rs 35.65 Cr against Rs 161.76 Cr a year earlier, a decrease of 77.96% YoY for the July to September quarter.
• Net profit: Rs 7.72 Cr against Rs 32.38 Cr, a 76.16% YoY fall that was a little smaller in percentage terms than the revenue decline.
• Gap: net profit fell 1.80 percentage points less than revenue in the quarter ended 30 September 2026, when both are set side by side as YoY percentages.
• Timing: the results date was 29 October 2026 and the comparison period for every YoY figure is July to September 2025.
• Next: the performance analysis turns the SENORES PHARMACEUTICALS L Q2 Results FY27 percentages into rupee terms and compares each line with the year-ago quarter.

SENORES PHARMACEUTICALS L Q2 Results FY27: Performance Analysis

The performance analysis shows that revenue and net profit both moved down YoY. Revenue shrank by Rs 126.11 Cr to reach Rs 35.65 Cr, and net profit shrank by Rs 24.66 Cr to reach Rs 7.72 Cr, so both lines sit well below the year-ago quarter and point the same way.

SENORES PHARMACEUTICALS L Q2 Results FY27 show net profit falling 76.16% against 77.96% for revenue, so each rupee of sales left slightly more profit behind than a year ago. Our results analysis treats that as a calculation on reported figures, and the drivers the company has disclosed follow in the business factors section.

SENORES PHARMACEUTICALS L Q2 Results FY27 leave Rs 161.76 Cr of year-ago revenue and Rs 32.38 Cr of year-ago net profit as a high comparison base for later quarterly results. Each new filing will be held up to the current marks as well. The business factors below set out what the SENORES PHARMACEUTICALS L Q2 Results disclosures put forward.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Margin Improvement – Net profit margin improved to 21.7% from 20.0% in the comparison quarter. This is consistent with net profit falling slightly less than revenue, and it shows in the quarterly results, despite negative YoY growth in sales, as a marginally larger share of sales kept as profit.

Return on Capital Employed – Return on capital employed was 15.66% in FY26. This is an annual measure for the previous financial year, so it describes the company’s longer record rather than the July to September quarter, and it adds longer-run context to the quarterly results.

Year-Ago Comparison Base – The year-ago quarter set revenue at Rs 161.76 Cr and net profit at Rs 32.38 Cr. Those are the figures against which the YoY changes in SENORES PHARMACEUTICALS L Q2 Results FY27 are measured, so the size of the percentages reflects that base as much as the current quarter.

FY27 Outlook After SENORES PHARMACEUTICALS L Q2 Results

From the business factors, the FY27 outlook rests on disclosed numbers, not guidance. FY27 full-year results depend on the quarters still to be reported, and each filing will show how revenue of Rs 35.65 Cr and net profit of Rs 7.72 Cr compare with what follows in the coming quarters.

SENORES PHARMACEUTICALS L Q2 Results FY27 are one of four quarters in the financial year, and later results analysis will place this one within the full FY27 picture. Net profit of Rs 7.72 Cr is the reference point, and the Univest Screener lists filings as they arrive. The risks come next.

Key Risks to Watch After SENORES PHARMACEUTICALS L Q2 Results FY27

Revenue Decline

Revenue declined 78.0% year on year to Rs 35.65 Cr in the latest quarter. A fall of that size is the main point to weigh in SENORES PHARMACEUTICALS L Q2 Results FY27, because every other line in the quarterly results depends on the sales base.

Net Profit Fall

Net profit fell 76.2% year on year to Rs 7.72 Cr. The decline moves in step with revenue, so the profit line offers no offset, and later filings will show whether the lower level holds.

Volatile Quarterly Profit

Quarterly net profit has been volatile, ranging from Rs 7.72 Cr to Rs 32.38 Cr over the last 5 quarters. A range that wide means one quarter is a limited guide to the next, and that leads into the conclusion.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

SENORES PHARMACEUTICALS L Q2 Results FY27 show revenue of Rs 35.65 Cr and net profit of Rs 7.72 Cr for July to September 2026. In these quarterly results both lines are lower than a year ago, and later filings will show how the pattern develops. Investors reading SENORES PHARMACEUTICALS L Q2 Results should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on SENORES PHARMACEUTICALS L Q2 Results FY27

What are SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. SENORES PHARMACEUTICALS L Q2 Results FY27 are the numbers for SENORES PHARMACEUTICALS L from July to September 2026, with revenue of Rs 35.65 Cr and net profit of Rs 7.72 Cr, as the Financial Highlights section sets out.

What is the results date for SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. The results date for SENORES PHARMACEUTICALS L Q2 Results FY27 is 29 October 2026, when the board meeting approved the quarter, which means the filing covers July to September 2026 as the opening paragraphs describe.

What revenue was reported in SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. SENORES PHARMACEUTICALS L reported revenue of Rs 35.65 Cr against Rs 161.76 Cr a year earlier, a 77.96% YoY decrease, and the Performance Analysis section turns that into rupee terms.

What net profit was reported in SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. SENORES PHARMACEUTICALS L reported net profit of Rs 7.72 Cr against Rs 32.38 Cr a year earlier, so the Key Takeaways section lists it as a 76.16% YoY fall.

How much YoY change did revenue show in SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. Revenue showed a YoY decline of 77.96%, moving from Rs 161.76 Cr to Rs 35.65 Cr, while the Performance Analysis section compares it with the slightly smaller fall in net profit.

Did net profit rise or fall in SENORES PHARMACEUTICALS L Q2 Results?

Ans. Net profit fell in SENORES PHARMACEUTICALS L Q2 Results, dropping from Rs 32.38 Cr to Rs 7.72 Cr, which means the Key Risks section looks at the size of that fall and the range of recent quarters.

How much YoY change did net profit show in SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. Net profit showed a YoY decline of 76.16%, a reduction of Rs 24.66 Cr, while the Key Takeaways section sets it beside the 77.96% decline in revenue.

What was the year-ago net profit in SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. The year-ago net profit was Rs 32.38 Cr, so the latest figure of Rs 7.72 Cr is lower, and the Financial Highlights table shows both numbers side by side.

What business factors shaped SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. The disclosed business factors are a net profit margin of 21.7% against 20.0%, return on capital employed of 15.66% in FY26, and the year-ago comparison base, covered in the Key Business Factors section.

What are the key risks after SENORES PHARMACEUTICALS L Q2 Results FY27?

Ans. The listed risks are the 78.0% revenue decline, the 76.2% net profit fall and a volatile quarterly profit range, which means the Key Risks section should be read with the quarterly results.

What is the outlook after SENORES PHARMACEUTICALS L Q2 Results?

Ans. FY27 full-year results for SENORES PHARMACEUTICALS L depend on the quarters still to come, so the outlook rests on later filings, as the FY27 Outlook section explains for revenue and net profit.

Where can I find the complete SENORES PHARMACEUTICALS L Q2 Results FY27 data?

Ans. The complete data sits in the Financial Highlights table above and in the Univest app, while the results date and results analysis sections explain each line of the quarterly results.